Richard Lirio to Adalimumab
This is a "connection" page, showing publications Richard Lirio has written about Adalimumab.
Connection Strength
1.084
-
Peyrin-Biroulet L, Loftus EV, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 2021 10; 161(4):1156-1167.e3.
Score: 0.749
-
Sands BE, Schreiber S, Lirio RA. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply. N Engl J Med. 2020 01 02; 382(1):93-94.
Score: 0.169
-
Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, T?r?ner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1215-1226.
Score: 0.166